[1] Stall B, Zach L, NingH, et al.  Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas[J]. Radiat Oncol, 2010, 5: 5-.   doi: 10.1186/1748-717X-5-5
[2] Yamasaki F, Sugiyama K, Ohtaki M, et al.  Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging[J]. Eur J Radiol, 2010, 73(3): 532-537.   doi: 10.1016/j.ejrad.2009.01.013
[3] Saconn PA, Shaw EG, Chan MD, et al.  Useof3.0-TMRIforstereotactic radiosurgery planning for treatment of brain metastases: a singleinstitution retrospective review[J]. Int J Radiat Oncol Biol Phys, 2010, 78(4): 1142-1146.
[4] Heiland S, Wick W, Bendszus M.  Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy?[J]. J Clin Oncol, 2010, 28(29): e591-.   doi: 10.1200/JCO.2010.30.3586
[5] Prabhakar R, Haresh KP, Ganesh T, et al.  Comparison of computed tomography and magnetic resonance based target volume in brain tumors[J]. J Cancer Res Ther, 2007, 3(2): 121-123.   doi: 10.4103/0973-1482.34694
[6] 李丹明, 朱锡旭, 武新虎.  不同MRI与CT图像融合对脑胶质瘤术后放疗靶区勾画的稳定性研究[J]. 中国癌症杂志, 2008, 18(1): 46-50.   doi: 10.3969/j.issn.1007-3639.2008.01.011
[7] Ulin K, Urie MM, Cherlow JM.  Results of a multi-institutional bench-mark test for cranial CT/MR image registration[J]. Int J Radiat Oncol Biol Phys, 2010, 77(5): 1584-1589.   doi: 10.1016/j.ijrobp.2009.10.017
[8] Farace P, Giri M, Meliadò G, et al.  Clinical target volume delineation in gliblastomas: pre-operative versus post-operative/preradiotherapy MRI[J]. Br J Radiol, 2011, 84(999): 271-278.   doi: 10.1259/bjr/10315979
[9] Pantelis E, Papadakis N, Verigos K, et al.  Integration of functional MRI and white matter tractography in stereotactic radiosurgery clinicalpractice[J]. Int J Radiat Oncol Biol Phys, 2010, 78(1): 257-267.   doi: 10.1016/j.ijrobp.2009.10.064
[10] Jonsson JH, Karlsson MG, Karlsson M, et al.  Treatment planning using MRI data: an analysis of the dose calculation accuracy for different treatment regions[J]. Radiat Oncol, 2010, 5: 62-.   doi: 10.1186/1748-717X-5-62
[11] Prabhakar R, Julka PK, Ganesh T, et al.  Feasibility of using MRI alone for 3D radiation treatment planning in brain tumors[J]. Jpn J Clin Oncol, 2007, 37(6): 405-411.   doi: 10.1093/jjco/hym050
[12] 孟庆勇, 余永强.  放射性脑损伤的MRI研究进展[J]. 国际医学放射学杂志, 2008, 31(5): 341-344.   doi: 10.3784/j.issn.1674-1897.2008.05.006
[13] Bobek-Billewicz B, Stasik-Pres G, Majchrzak H, et al.  Differentiation between brain tumor recurrence and radiation in jury using perfusion, diffusion-weighted imaging and MR spectroscopy[J]. Folia Neuropathol, 2010, 48(2): 81-92.
[14] Pra t R, Galeano I, Lucas A, et al.  Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2(-18F)fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas[J]. J Clin Neurosci, 2010, 17(1): 50-53.   doi: 10.1016/j.jocn.2009.02.035
[15] Mitsuya K, Nakasu Y, Horiguchi S, et al.  Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery[J]. JNeurooncol, 2010, 99(1): 81-88.   doi: 10.1007/s11060-009-0106-z
[16] Zeng QS, Li CF, Zhang K, et al.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury[J]. J Neurooncol, 2007, 84(1): 63-69.   doi: 10.1007/s11060-007-9341-3
[17] Sundgren PC.  MR spectroscopy in radiation injury[J]. AJNR Am J Neuroradiol, 2009, 30(8): 1469-1476.   doi: 10.3174/ajnr.A1580